Geographic Atrophy

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

"Modern Family" actor and his mother, Jamey, are sharing their family’s story of GA and AMD to raise awareness of the disease.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

Garg reported the 30-month data showing that patients receiving pegcetacoplan experienced an increasing treatment effect compared with sham (ie, a decrease in GA lesion area over time).

The podcast by Cognition Therapeutics features a discussion with retinal specialists.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.

According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Astellas Pharma Inc. announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for Iveric Bio’s avacincaptad pegol (ACP).

According to the company, the solution slowed the loss of photoreceptors and disease progression as early as six months.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

Apellis Pharmaceuticals, Inc. presented results from the GALE extension study at the 2023 ASRS annual meeting in Seattle. The results indicated that continuous treatment with SYFOVRE (pegcetacoplan injection) for 30 months continued to show increasing beneficial effects.

Tarek Hassan, MD, spoke with our team about a novel glyco-mimetic nanoparticle, Aviceda AVD-104, being developed for the treatment of geographic atrophy.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, spoke with our team to share information on the GALE extension study.

In presentations at the ASRS 41st Annual Meeting in Seattle, additional analyses support consistent protection from vision loss.

During presentations at the ASRS 41st Annual Meeting in Seattle, Apellis noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis, and no events were reported in clinical trials.

At the 2023 ASRS meeting in Seattle, Washington, Carl Danzig, MD, caught up with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy.

The American Society of Retina Specialists is hosting its annual meeting this year in Seattle, Washington. Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

Cognition Therapeutics has dosed the first participant in the phase 2 MAGNIFY study of CT1812. This oral therapy is being studied as a for geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

Akari remains on track and plans to submit an IND application to the US FDA in the first half of 2024, and plans on starting clinical trials in the second half of 2024